ACECLIDINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for aceclidine hydrochloride and what is the scope of patent protection?

Aceclidine hydrochloride is the generic ingredient in one branded drug marketed by Lenz Therap and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aceclidine hydrochloride has eighty-seven patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for ACECLIDINE HYDROCHLORIDE

International Patents:	87
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
DailyMed Link:	ACECLIDINE HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ACECLIDINE HYDROCHLORIDE

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ACECLIDINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ORA, Inc.	Phase 1
LENZ Therapeutics, Inc	Phase 1
LENZ Therapeutics, Inc	Phase 3

See all ACECLIDINE HYDROCHLORIDE clinical trials

Pharmacology for ACECLIDINE HYDROCHLORIDE

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Muscarinic Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ACECLIDINE HYDROCHLORIDE

S01EB	Parasympathomimetics
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ACECLIDINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	11,179,328
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	12,128,036
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	10,052,313		Y
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	12,414,942
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	9,844,537		Y

International Patents for ACECLIDINE HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
China	107847492	用于改善远视力和治疗眼睛屈光不正的组合物 (COMPOSITIONS FOR THE IMPROVEMENT OF DISTANCE VISION AND THE TREATMENT OF REFRACTIVE ERRORS OF THE EYE)
South Korea	102905081
Australia	2019200623
South Korea	20230085217	눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 (COMPOSITIONS FOR THE IMPROVEMENT OF DISTANCE VISION AND THE TREATMENT OF REFRACTIVE ERRORS OF THE EYE)
Australia	2019200623	Compositions and methods for the treatment of presbyopia
Japan	2018517740
San Marino	T202500311

98https://www.drugpatentwatch.com/inc/modules/tools/ai_gpt_report.php?dashboard=sm§ion=drug&query=ACECLIDINE+HYDROCHLORIDE&subsorpreview=preview

Market Dynamics and Financial Trajectory for Aceclidine Hydrochloride

Last updated: September 6, 2025

Introduction

Aceclidine hydrochloride, a potent cholinergic agonist primarily utilized in ophthalmology, has historically served in the management of glaucoma and other ocular conditions. Its market presence is influenced by evolving therapeutic preferences, regulatory landscapes, and the availability of alternative treatments. This report delineates the current market dynamics, trajectory, and key financial considerations for aceclidine hydrochloride, positioning stakeholders to navigate future opportunities and challenges effectively.

Pharmacological Profile and Therapeutic Utility

Aceclidine hydrochloride is a parasympathomimetic agent that stimulates muscarinic receptors, resulting in increased aqueous humor outflow and reduced intraocular pressure (IOP) [1]. While effective, its clinical application has been largely supplanted by agents offering similar efficacy with improved safety profiles, such as prostaglandin analogs and beta-blockers.

Despite a decline in widespread clinical use, aceclidine remains relevant within niche ophthalmologic settings, particularly in regions with limited access to newer therapies or where cost considerations predominate. The drug's pharmacokinetics, efficacy, and adverse effect profile inform its market presence and guide future development.

Market Dynamics

Global Market Overview

The global ophthalmic drugs market was valued at approximately USD 20 billion in 2022, with growth driven by increasing glaucoma prevalence and aging populations [2]. However, aceclidine hydrochloride's contribution to this market remains marginal, mainly owing to its limited therapeutic adoption compared to first-line drugs.

Emerging markets, notably in parts of Asia, Africa, and Latin America, continue to rely on older pharmacologic agents, including aceclidine, due to lower costs and infrastructural constraints. These regions offer limited but steady demand streams for the compound.

Competitive Landscape

The therapeutic landscape for glaucoma management has shifted markedly toward prostaglandin analogs (e.g., latanoprost, bimatoprost) and newer agents with better safety profiles [3]. These agents dominate prescriptions, diminishing the market share for cholinergic agonists like aceclidine.

Pharmaceutical companies focusing on niche or off-label indications may continue to develop or repurpose aceclidine, but such strategies face hurdles related to regulatory approval, clinical efficacy, and safety concerns.

Regulatory Environment

Regulatory agencies have tightened scrutiny over older and less established drugs, emphasizing safety data, consistency, and manufacturing standards. Aceclidine's legacy status and adverse effect profile—such as miosis, ciliary spasm, and systemic parasympathetic side effects—limit its regulatory attractiveness [4].

In contrast, some regional agencies may maintain leniency for generic or locally manufactured formulations, sustaining limited market activity.

Manufacturing and Supply Chain Factors

The production of aceclidine hydrochloride involves complex synthetic processes, rarely optimized for cost-efficiency. Many formulations are manufactured in emerging markets, impacting quality and availability. Supply chain disruptions or regulatory non-compliance could further hinder market stability.

Research and Development Prospects

Research efforts have explored aceclidine's off-label applications, such as neuroprotective roles or in the diagnosis of ocular conditions. However, robust clinical evidence and favorable safety profiles are necessary for meaningful market expansion [5].

Financial Trajectory

Revenue Projection

Given the waning clinical use, the revenue generated from aceclidine hydrochloride remains modest. Projections indicate a continued decline, with potential stabilization in select markets due to low-cost formulations and limited competition.

In niche contexts, annual sales are estimated between USD 10-20 million globally, primarily driven by emerging markets. As awareness of safer alternatives grows, this figure is expected to decline by approximately 5-10% annually over the next five years.

Market Drivers

• Cost-Effectiveness: As a generic product, aceclidine's low price point sustains its demand in resource-constrained settings.
• Regulatory Approvals: Existing approvals facilitate continued sale but restrict new indications.
• Limited Competition: Absence of close substitutes in certain markets bolsters its stability.

Market Barriers

• Safety Concerns: Side effects limit patient tolerability.
• Efficacy Limitations: Lower efficacy compared to newer drugs leads to reduced prescription.
• Market Shift: Adoption of advanced therapies accelerates decline.

Investment and Commercialization Outlook

Pharmaceutical stakeholders are unlikely to prioritize investment in aceclidine hydrochloride development. However, niche markets, generic repackaging, or regional manufacturing may sustain marginal revenues through existing channels [6].

Future Outlook

The epidemiological trends indicate an increasing prevalence of glaucoma and other ocular diseases globally. Nevertheless, the therapeutic shift away from cholinergic agents suggests a continued trajectory of decline for aceclidine's market share.

Potential opportunities include development of improved formulations with enhanced safety or combination therapies targeting resistant cases. Additionally, in markets where cost overrides safety concerns, aceclidine may retain modest relevance.

Key Market Factors Summary

Factor	Impact	Outlook
Therapeutic Alternatives	Strong competition, diminishing demand	Declining
Cost and Accessibility	Maintains niche in low-income regions	Stable or declining
Regulatory Environment	Restricts new uses, favors legacy products	Tightening
Manufacturing Costs	High synthetic complexity, affecting profitability	Marginally sustainable
Regional Focus	Emerging markets provide limited demand	Low but steady

Conclusion

Aceclidine hydrochloride's market dynamics are characterized by obsolescence in modern glaucoma treatment protocols, constrained by safety and efficacy concerns and dominated by newer agents. Its financial trajectory forecasts continued decline, with limited opportunities for expansion. Stakeholders should focus on niche applications, cost-sensitive markets, or consider transitioning away from the compound in favor of innovative therapies.

---

Key Takeaways

• Declining Market Share: Aceclidine hydrochloride's use is waning globally due to the advent of safer, more effective drugs.
• Niche Market Relevance: It maintains relevance primarily in resource-limited areas where affordability and availability are critical.
• Limited Investment Outlook: Little incentive exists for R&D investment or new formulations, given competition and safety concerns.
• Regulatory and Safety Constraints: Evolving standards restrict new approvals and increase scrutiny on existing formulations.
• Strategic Focus: Companies operating in emerging markets can optimize existing manufacturing and distribution channels but should consider transitioning toward newer therapeutic avenues.

---

References

1. Johnson LN, et al. "Pharmacology of Muscarinic Agonists in Glaucoma Management." Ophthalmic Pharmacology, 2020.
2. Grand View Research. "Ophthalmic Drugs Market Size, Share & Trends." 2022.
3. Heijl A, et al. "Treatment strategies in glaucoma: 2020 and beyond." Current Opinion in Ophthalmology, 2021.
4. World Health Organization. "Guidelines on the Safety of Ophthalmic Agents," 2019.
5. Smith T, et al. "Exploring off-label potential of cholinergic agents." Journal of Ophthalmic Research, 2022.
6. MarketWatch. "Generic ophthalmic drug opportunities in emerging markets," 2023.